ONO4057 is a Leukotriene B₄ receptor antagonist, with an IC₅₀ of 0.7±0.3 μM. IC50 & Target: IC50: 0.7±0.3 μM (Leukotriene B₄ receptor)^[1] In Vivo: Mean animal survivals of the ONO4057-treated animals significantly prolong to 21.0±4.4 days compare with 12.0±0.6 days in control group. Histological findings from grafts taken on day 7 show that severe focal cellular infiltration is observed in both groups, but the degree of hepatocyte necrosis in ONO4057-treated anmimals is milder than that in control group^[2].